Skip to main content
SpringerLink
Log in

Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses

Amphotericin B Konzentrationen in Faeces und im Blut gesunder, freiwilliger Probanden nach oraler Verabreichung verschiedener Dosen

  • Originalia
  • Published:
Infection Aims and scope Submit manuscript

Summary

We have investigated which dose of amphotericin B can be regarded as an optimal oral dose for the prophylaxis of colonization of the digestive tract byCandida species. Ten human volunteers were given different doses; each dose was administered for five days. The results of this study revealed that although oral doses of 0.5 g amphotericin B per day resulted in sufficient concentrations in 70% of the faecal samples obtained during application, higher doses (1.5 or 2 g per day) were required to obtain detectable amphotericin B activity in 95% and 100% of the samples, respectively. A daily dose of 1.0 g is recommended. We have taken into consideration the variation in amphotericin B concentrations among individuals following this recommended dose.

Zusammenfassung

In der vorliegenden Arbeit wurden Untersuchungen zur optimalen Dosierung von Amphotericin B bei oraler prophylaktischer Verabreichung zum Schutz vor Besiedelung des Verdauungstraktes mitCandida Spezies vorgenommen. Zehn freiwillige Probanden erhielten verschiedene Dosen, von denen jede fünf Tage lang verabreicht wurde. Die Ergebnisse der Studie zeigten, daß zwar mit einer täglichen oralen Dosis von 0,5 g Amphotericin B in 70% der während der Applikation gewonnenen Stuhlproben ausreichend hohe Konzentrationen der Substanz vorlagen, doch wurden erst mit Dosen von 1,5 g oder 2 g Amphotericin B pro Tag in 95% bzw. 100% der Proben meßbare Konzentrationen erzielt. Unter Berücksichtigung der interindividuellen Schwankungen der Amphotericin-B-Konzentrationen wird eine Dosis von 1,0 g pro die empfohlen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Literature

  1. Krick, J. A., Remington, J. S. Opportunistic invasive fungal infections in patients with leukemia and lymphoma. Clin. Haematol. 5 (1976) 249–310.

    Google Scholar 

  2. Waaij, D. van der, Tielemans-Speltie, T. M., de Roeck-Houben, A. M. J. Infection by and distribution of biotypes ofEnterobacteriaceae species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe. Infection 3 (1977) 188–194.

    Google Scholar 

  3. Schimpff, S. C., Young, V. M., Greene, W. H., Vermeulen, G. D., Moody, M. R., Wiernik, P. H. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann. Int. Med. 77 (1972) 707–714.

    Google Scholar 

  4. Bender, J. F., Schimpff, S. C., Young, V. M., Fortner, C. L., Love, L. J., Brouillet, M. D., Wiernik, P. H. A comparative trial of tobramycin vs gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemic patients. Eur. J. Cancer 15 (1979) 34–44.

    Google Scholar 

  5. Bodes, G. P., Rodriguez, V. Infections in cancer patients on a protected environment-prophylactic antibiotic program. Am. J. Med. 59 (1975) 497–504.

    Google Scholar 

  6. Schimpff, S. C., Greene, W. H., Young, V. M., Fortner, C. L., Jepsen, L., Cusack, N., Block, J. B., Wiernik, P. H. Infection prevention in acute non-lymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann. Int. Med. 82 (1975) 351–358.

    Google Scholar 

  7. Guiot, H. F. L., Furth, R. van Partial antibiotic decontamination. Br. Med. J. 1 (1977) 800–802.

    Google Scholar 

  8. Sleijfer, D. T., Mulder, N. H., Vries-Hospers, H. G. de, Fidler, V., Nieweg, H. O., Waaij, D. van der, Saene, H. K. F. van Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur. J. Cancer 16 (1980) 859–869.

    Google Scholar 

  9. Walter, A. H., Heilmeyer, L. Antibiotika-Fibel. Antibiotika- und Chemotherapeutika-Therapie mikrobieller Infektionen, 4th ed., Georg Thieme Verlag, Stuttgart 1975, pp. 666–672.

    Google Scholar 

  10. Hofstra, W., Vries-Hospers, H. G. de, Waaij, D. van der Concentrations of nystatin in faeces after oral administration of various doses. Infection 4 (1979) 166–170.

    Google Scholar 

  11. Goss, W. A., Cimijotti. B.: Evaluation of an automatic diluting device for microbiological application. Appl. Microbiol. (1968) 1414–1416.

  12. Louria, D. B. Some aspects of the absorption, distribution and excretion of amphotericin B in man. Antibiot. Med. Clin. Ther. 5 (1957) 295–301.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Medical Microbiology, University Hospital of Groningen, Oostersingel 59, 9713 EZ, Groningen, The Netherlands

    W. Hofstra,  Hilly G. de Vries-Hospers &  D. van der Waaij

Authors
  1. W. Hofstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hilly G. de Vries-Hospers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. van der Waaij
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hofstra, W., de Vries-Hospers, H.G. & van der Waaij, D. Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses. Infection 10, 223–227 (1982). https://doi.org/10.1007/BF01666915

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01666915

Keywords

Search

Navigation